Stockscreener 앱 받기
14.48
14.83%
1.87
시간 외 거래:
13.76
-0.72
-4.97%
전일 마감가:
$12.61
열려 있는:
$12.9
하루 거래량:
195.78K
Relative Volume:
1.80
시가총액:
$83.82M
수익:
-
순이익/손실:
$-74.14M
주가수익비율:
-1.2713
EPS:
-11.39
순현금흐름:
$-65.70M
1주 성능:
+13.30%
1개월 성능:
-20.96%
6개월 성능:
-49.69%
1년 성능:
+29.06%
1일 변동 폭
$12.90
$14.63
1주일 범위
$10.80
$14.63
52주 변동 폭
$9.62
$92.00
인스틸 바이오 Stock (TIL) Company Profile
명칭
Instil Bio Inc
전화
(972) 499-3350
주소
3963 MAPLE AVENUE, DALLAS
TIL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
14.48 | 83.82M | 0 | -74.14M | -65.70M | -11.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
인스틸 바이오 Stock (TIL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Perform |
| 2024-04-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-11-01 | 다운그레이드 | Truist | Buy → Hold |
| 2021-08-13 | 개시 | Robert W. Baird | Outperform |
| 2021-04-13 | 개시 | Cowen | Outperform |
| 2021-04-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-04-13 | 개시 | Truist | Buy |
모두보기
인스틸 바이오 주식(TIL)의 최신 뉴스
Financial Metrics Check: Microbot Medical Inc (MBOT)’s Ratios for Trailing Twelve Months - DWinneX
Investor’s Toolkit: Key Ratios for Assessing Instil Bio Inc (TIL)’s Performance - DWinneX
TIL’s Stock Market Adventure: -33.05% YTD Growth Amidst Volatility - investchronicle.com
Have you been able to find a good deal on Instil Bio Inc’s shares? - uspostnews.com
Instil Bio Inc (TIL) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
(TIL) Trading Report - news.stocktradersdaily.com
GT’s Debt-to-Equity Ratio at 1.85: What It Means for Goodyear Tire & Rubber Co’s Future - investchronicle.com
Where are the Opportunities in (TIL) - news.stocktradersdaily.com
Tumor-infiltrating Lymphocyte (TIL) Therapies Global Market Report 2025: 75+ Therapies are Under Development and 100+ Clinical Trials are Underway Globally - GlobeNewswire Inc.
SEC Form 424B5 filed by Instil Bio Inc. - Quantisnow
(TIL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
The Significance of Moving Averages in New Found Gold Corp Inc. (NFGC) Price Performance - investchronicle.com
Instil Bio, Inc. SEC 10-K Report - TradingView
Instil Bio Reports 2024 Financial Results and Outlook - TipRanks
Instil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last year - TipRanks
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
When (TIL) Moves Investors should Listen - Stock Traders Daily
Institutions along with private equity firms who hold considerable shares inInstil Bio, Inc. (NASDAQ:TIL) come under pressure; lose 12% of holdings value - Simply Wall St
Instil Bio: Time To Hop On The Summit Wave? (NASDAQ:TIL) - Seeking Alpha
(TIL) Technical Data - Stock Traders Daily
Private equity firms who hold 38% of Instil Bio, Inc. (NASDAQ:TIL) gained 34%, institutions profited as well - Yahoo Finance
(TIL) Investment Analysis and Advice - Stock Traders Daily
(TIL) Investment Report - Stock Traders Daily
What Makes Instil Bio (TIL) a New Buy Stock - MSN
Instil Bio Announces Clinical Progress in China for - GlobeNewswire
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody - Marketscreener.com
Instil Bio Advances Lung Cancer Treatment: First Patient Dosed in Phase 1b/2 Trial of Novel PD-L1xVEGF Therapy - StockTitan
Instil Bio Stock Soars After Jefferies Upgrade On 'Early Mover' Cancer Drug Candidate: Retail Jubilant - MSN
Jefferies Upgrades Instil Bio (TIL) - MSN
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside - Benzinga
These DFW stocks soared in 2024 - WFAA
How To Trade (TIL) - Stock Traders Daily
Instil Bio Secures Loan to Refinance Facility - MSN
Long Term Trading Analysis for (TIL) - Stock Traders Daily
Trend Tracker for (TIL) - Stock Traders Daily
Instil Bio’s Strategic Shift To SYN-2510: A Speculative ‘Buy’ Opportunity (NASDAQ:TIL) - Seeking Alpha
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance
Biontech acquiring PM-8002 through $950M Biotheus buyout - BioWorld Online
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Instil Bio Secures Global Rights to PD-L1xVEGF Drug, Reports $122.9M Cash Position | TIL Stock News - StockTitan
BioNTech Drops $800m To Acquire Bispecific Specialist Biotheus - insights.citeline.com
2 Stocks Up Over 700% in 2024 That Could Soar Even Further - AOL
JMP Securities initiates Instil Bio shares at Market Perform on public offering - Investing.com Australia
Instil Bio, Inc.'s (NASDAQ:TIL) stock price dropped 18% last week; private equity firms would not be happy - Simply Wall St
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold? - Nasdaq
Analysis of Curative Ventures V LLC's Strategic Reduction in Instil Bio Inc - GuruFocus.com
(TIL) Long Term Investment Analysis - Stock Traders Daily
Baird maintains price target on Instil Bio stock, stays upbeat - Investing.com India
5 Top NASDAQ Biotech Stocks of 2024 - Investing News Network
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77% - Baystreet.ca
BOXER CAPITAL, LLC Acquires New Stake in Instil Bio Inc - GuruFocus.com
인스틸 바이오 (TIL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
2.63%
자본화:
|
볼륨(24시간):